Management to host conference call and webcast today at 4:30 p.m. ET LEXINGTON, Mass., Nov. 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company ...
Record free cash flow of approximately $700 million and achieved net cash position Increased 2025 share buyback target by 20% to $600 million and dividend by 17%On track to meet annual guidance TORONT ...
Amgen today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback